Supplementary Table S4 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations

Authors:

Open Access

Publisher website

2 February 2026

other
Published by American Association for Cancer Research (AACR)

DOI:10.1158/0008-5472.31228776

Abstract

Table S4 shows the mutational landscape of EGFR mutant PDX models

Keywords